Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 2:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,132 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Newborn Infants Clear all
Terminated Phase 3 Interventional Results available

Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria

NCT03219164
View directory record Official record
Conditions
Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization, Cystic Fibrosis
Interventions
AZLI, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
3 Months to 18 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
12
States / cities
San Francisco, California • Washington D.C., District of Columbia • St. Petersburg, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Sep 5, 2026, 2:30 PM EDT
Completed Not applicable Interventional

MD2Me - Texting to Promote Chronic Disease Management

NCT01253733
View directory record Official record
Conditions
Cystic Fibrosis, Inflammatory Bowel Disease, Type 1 Diabetes, Chronic Disease Management
Interventions
MD2ME
Behavioral
Lead sponsor
Huang, Jeannie, M.D.
Individual
Eligibility
14 Years to 22 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Sep 5, 2026, 2:30 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Quantitative Assessment of Sucking for Early Diagnosis of Brain Injury in Infants at High Risk

NCT03246243
View directory record Official record
Conditions
Hypoxic-Ischemic Encephalopathy, Hypoglycemia, Neonatal Abstinence Syndrome
Interventions
nfant feeding solution
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 6 Months
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Sep 5, 2026, 2:30 PM EDT
Not listed No phase listed Observational

Unbound Bilirubin Levels in Healthy Term and Late Preterm Infants

NCT03237715
View directory record Official record
Conditions
Neonatal Jaundice
Interventions
Assessment of unbound bilirubin levels
Other
Lead sponsor
Rutgers University
Other
Eligibility
6 Hours to 7 Days
Enrollment
180 participants
Timeline
2017 – 2019
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Sep 5, 2026, 2:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Development of Standards for the New Ballard Maturation Score

NCT01203449
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Pregnancy
Interventions
Not listed
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 48 Hours
Enrollment
1,090 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 1996
U.S. locations
11
States / cities
Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 5, 2026, 2:30 PM EDT
Completed No phase listed Observational

Application of a Systematic Developmental Assessment to a Novel Population: Infants With Rare Genetic Disorders

NCT03967743
View directory record Official record
Conditions
Genetic Disease, Genetic Syndrome, Genetic Predisposition to Disease, Development, Infant, Development, Child
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 4 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 5, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment

NCT05437120
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-121/TEZ/D-IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Miami, Florida • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Sep 5, 2026, 2:30 PM EDT
Recruiting Phase 2 Interventional

Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)

NCT07169279
View directory record Official record
Conditions
Achondroplasia
Interventions
Infigratinib is provided as a single dose of minitablets for oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration, Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
0 Years to 32 Months
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Oakland, California • Baltimore, Maryland • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 5, 2026, 2:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Risk of Asthma in Infants With Atopic Dermatitis

NCT00459576
View directory record Official record
Conditions
Asthma, Eczema, Dermatitis, Atopic
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
2 Months to 7 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Sep 5, 2026, 2:30 PM EDT
Completed Phase 4 Interventional Results available

Preterm Infant Inhaled Albuterol Dosing

NCT02447250
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Very Low Birth Weight
Interventions
Varied albuterol dose response
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
14 Days and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Sep 5, 2026, 2:30 PM EDT
Recruiting No phase listed Observational

Brain Blood Flow and Cerebral Autoregulation Monitoring in Critically Ill Children

NCT07613918
View directory record Official record
Conditions
Critical Illness, Pediatric Critical Illness, Respiratory Failure, Traumatic Brain Injury, Cardiac Arrest
Interventions
Transcranial Doppler
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
1 Day to 17 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 5, 2026, 2:30 PM EDT
Completed No phase listed Observational

A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function

NCT04038047
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Nicole Hamblett
Other
Eligibility
12 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
56
States / cities
Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 5, 2026, 2:30 PM EDT
Completed Not applicable Interventional

Feeding During Ibuprofen or Indomethacin Treatment of Preterm Infants

NCT00728117
View directory record Official record
Conditions
Patent Ductus Arteriosus
Interventions
feeding, fasting
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
23 Weeks to 33 Weeks
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
14
States / cities
San Francisco, California • San Jose, California • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2012 · Synced Sep 5, 2026, 2:30 PM EDT
Withdrawn Phase 1 Interventional

Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II

NCT05238324
View directory record Official record
Conditions
Mucopolysaccharidosis II
Interventions
Genetic HMI-203
Biological
Lead sponsor
Homology Medicines, Inc
Industry
Eligibility
18 Years to 45 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
5
States / cities
Oakland, California • New Haven, Connecticut • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Sep 5, 2026, 2:30 PM EDT
Completed Phase 1 Interventional

SD Cystic Fibrosis Study

NCT00605761
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
SB656933
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
16 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Palo Alto, California • Minneapolis, Minnesota • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 18, 2012 · Synced Sep 5, 2026, 2:30 PM EDT
Terminated No phase listed Observational

Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung

NCT02113397
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
TOBI™ Podhaler™ 112 mg inhaled twice daily, Colistimethate 75 mg inhaled two times daily
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
12 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Sep 5, 2026, 2:30 PM EDT
Withdrawn No phase listed Observational

Electrocardiography Versus Pulse Oximetry for Newborn Heart Rate Determination

NCT01256346
View directory record Official record
Conditions
Prematurity
Interventions
Apparatuses
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
Up to 20 Minutes
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Sep 5, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism

NCT04538989
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
RZ358 Sequential Group Cohort 1, RZ358 Sequential Group Cohort 2, RZ358 Sequential Group Cohort 3, RZ358 Sequential Group Cohort 4
Drug
Lead sponsor
Rezolute
Other
Eligibility
2 Years to 45 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Sep 5, 2026, 2:30 PM EDT
Completed Phase 1 Interventional

The Use of Eculizumab in HELLP Syndrome

NCT04103489
View directory record Official record
Conditions
HELLP Syndrome (HELLP), Third Trimester, Complement Abnormality, Morbidity;Newborn, Maternal Injury, Preeclampsia Severe
Interventions
Eculizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Sep 5, 2026, 2:30 PM EDT
Active, not recruiting Not applicable Interventional

Developmental Intervention for Hospitalized Newborns With Congenital Heart Disease

NCT05885113
View directory record Official record
Conditions
Cardiology, Infant Development, Development Delay
Interventions
NIDCAP Developmental Care
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 4 Months
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 5, 2026, 2:30 PM EDT
Recruiting Not applicable Interventional

GERD Infant Feeding Therapeutics Trial (GIFT Trial)

NCT06114836
View directory record Official record
Conditions
GERD in Infants
Interventions
Omeprazole, AR formula
Drug · Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Day to 8 Months
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 5, 2026, 2:30 PM EDT
Completed Not applicable Interventional

Comparing FEES to VFSS in Diagnosing Laryngeal Penetration and Aspiration in Infants in the NICU

NCT02003287
View directory record Official record
Conditions
Deglutition Disorders
Interventions
VFSS, FEES
Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
37 Weeks and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 5, 2026, 2:30 PM EDT
Withdrawn No phase listed Observational

Intermittent Versus Continuous Infusion Meropenem in Cystic Fibrosis

NCT02048163
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Dayton Children's Hospital
Other
Eligibility
7 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 5, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

NCT00510484
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Pancrelipase Delayed Release, Placebo Comparator
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
19
States / cities
Long Beach, California • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2010 · Synced Sep 5, 2026, 2:30 PM EDT